Gland Pharma · NSE: GLAND · BSE: 543245
Q4 FY23 results · Jan–Mar 2023
Gland Pharma reported revenue from operations of ₹785.01 crore (down 28.8% from Q4 FY22) and net profit of ₹78.68 crore (down 72.5% from Q4 FY22) for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 785.01 | 1,103.01 | −28.8% | 938.29 | −16.3% |
| Other income | 38.94 | 65.23 | −40.3% | 61.51 | −36.7% |
| Total income | 823.95 | 1,168.25 | −29.5% | 999.80 | −17.6% |
| Profit before tax | 111.15 | 380.48 | −70.8% | 310.85 | −64.2% |
| Net profit for the period | 78.68 | 285.90 | −72.5% | 231.95 | −66.1% |
| EPS, basic (₹) | 4.78 | 17.40 | −72.5% | 14.08 | −66.1% |
| Net margin (%) | 10.0 | 25.9 | 24.7 |
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 785.42 | 1,103.01 | −28.8% | 925.90 | −15.2% |
| Other income | 38.94 | 65.23 | −40.3% | 61.51 | −36.7% |
| Total income | 824.36 | 1,168.25 | −29.4% | 987.41 | −16.5% |
| Profit before tax | 111.91 | 380.56 | −70.6% | 305.24 | −63.3% |
| Net profit for the period | 79.21 | 285.98 | −72.3% | 227.54 | −65.2% |
| EPS, basic (₹) | 4.81 | 17.41 | −72.4% | 13.82 | −65.2% |
| Net margin (%) | 10.1 | 25.9 | 24.6 |
Consolidated
- Filed with BSE
- 19 May 2023, 17:25 IST
- Board meeting
- 18 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 19 May 2023, 17:25 IST
- Board meeting
- 18 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE